| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Minireview
Molecular Advances in Pretargeting Radioimunotherapy with Bispecific Antibodies1
IBC Pharmaceuticals, L. L. C., Morris Plains, New Jersey 07950 [C-H. C., E. A. R.]; Immunomedics, Inc., Morris Plains, New Jersey 07950 [C-H. C., W. M., H. J. H.]; Garden State Cancer Center, Belleville, New Jersey 07109 [R. M. S., H. K., D. M. G.]; and Inserm U463, 44093 Nantes, Cedex 01, France [J-F. C., J. B.]
The use of antibodies against tumor-associated cell surface antigens for the targeted delivery of radionuclides was introduced >20 years ago. Although encouraging results have been achieved with radiolabeled antibodies in the management of hematopoietic malignancies, there remains a need for successfully treating solid tumors with this modality. One promising approach involving pretargeted delivery of radionuclides has been shown to be capable of significantly increasing the radioactive uptake in tumor relative to normal organs, thereby potentially improving the efficacy of both detection and therapy of cancer. Uncoupling of the radionuclide from the tumor-targeting antibody allows the relatively slow process of antibody localization and clearance to occur before a very rapid and highly specific delivery of the radioactive payload carried on a small molecule, such as a peptide. This minireview discusses the various strategies and advancements made since the concept of pretargeting was proposed in the mid-1980s, with emphasis on those comprising bispecific antibodies for cancer therapy. Critical aspects of these pretargeting systems for achieving higher tumor:nontumor ratios are considered. In addition, both preclinical and clinical results obtained from a pretargeting method known as the Affinity Enhancement System are presented. Future directions of pretargeting technology are also suggested.
This article has been cited by other articles:
|
|
 |
|
  D. M. Goldenberg Proceedings of the Eleventh Conference on Cancer Therapy with Antibodies and Immunoconjugates. October 12-14, 2006. Parsippany, New Jersey, USA. Clin. Cancer Res., September 15, 2007; 13(18 Pt 2): 5499s - 5660s. [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Brard, H. Karacay, R. Stein, R. M. Sharkey, M. J. Mattes, C.-H. Chang, E. A. Rossi, W. J. McBride, and D. M. Goldenberg A Divalent Hapten-Peptide Induces Apoptosis in Human Non Hodgkin Lymphoma Cell Lines Targeted by Anti-CD20 x Anti-Hapten Bispecific Antibodies Clin. Cancer Res., September 15, 2007; 13(18): 5564s - 5571s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sezeur, F.P. Chatelet, Ch. Cywiner, Cl. de Labriolle-Vaylet, C. Chastang, Cl. Billotey, M. Malafosse, D. Gallot, P. Betton, F. Montravers, et al. Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging Clin. Cancer Res., September 15, 2007; 13(18): 5592s - 5597s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pantelias, J. M. Pagel, N. Hedin, L. Saganic, S. Wilbur, D. K. Hamlin, D. S. Wilbur, Y. Lin, D. Stone, D. Axworthy, et al. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas Blood, June 1, 2007; 109(11): 4980 - 4987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Moosmayer, D. Berndorff, C.-H. Chang, R. M. Sharkey, A. Rother, S. Borkowski, E. A. Rossi, W. J. McBride, T. M. Cardillo, D. M. Goldenberg, et al. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin. Cancer Res., September 15, 2006; 12(18): 5587 - 5595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shen, M. D. Vil, X. Jimenez, M. Iacolina, H. Zhang, and Z. Zhu Single Variable Domain-IgG Fusion: A NOVEL RECOMBINANT APPROACH TO Fc DOMAIN-CONTAINING BISPECIFIC ANTIBODIES J. Biol. Chem., April 21, 2006; 281(16): 10706 - 10714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy J. Clin. Oncol., February 10, 2006; 24(5): 823 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kraeber-Bodere, C. Rousseau, C. Bodet-Milin, L. Ferrer, A. Faivre-Chauvet, L. Campion, J.-P. Vuillez, A. Devillers, C.-H. Chang, D. M. Goldenberg, et al. Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial J. Nucl. Med., February 1, 2006; 47(2): 247 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Forster, E. B. Santos, P. M. Smith-Jones, P. Zanzonico, and S. M. Larson Pretargeted Radioimmunotherapy with a Single-Chain Antibody/Streptavidin Construct and Radiolabeled DOTA-Biotin: Strategies for Reduction of the Renal Dose J. Nucl. Med., January 1, 2006; 47(1): 140 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Karacay, P.-Y. Brard, R. M. Sharkey, C.-H. Chang, E. A. Rossi, W. J. McBride, D. R. Ragland, I. D. Horak, and D. M. Goldenberg Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft Clin. Cancer Res., November 1, 2005; 11(21): 7879 - 7885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Goldenberg Introduction to the Tenth Conference on Cancer Therapy with Antibodies and Immunoconjugates Clin. Cancer Res., October 1, 2005; 11(19): 7045s - 7046s. [Full Text] [PDF]
|
|
|
|
|
|
E. A. Rossi, C.-H. Chang, M. J. Losman, R. M. Sharkey, H. Karacay, W. McBride, T. M. Cardillo, H. J. Hansen, Z. Qu, I. D. Horak, et al. Pretargeting of Carcinoembryonic Antigen-Expressing Cancers with a Trivalent Bispecific Fusion Protein Produced in Myeloma Cells Clin. Cancer Res., October 1, 2005; 11(19): 7122s - 7129s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. DeNardo, C. M. Richman, H. Albrecht, P. A. Burke, A. Natarajan, A. Yuan, J. P. Gregg, R.T. O'Donnell, and G. L. DeNardo Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer Clin. Cancer Res., October 1, 2005; 11(19): 7187s - 7194s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Jaggi, S. V. Seshan, M. R. McDevitt, K. LaPerle, G. Sgouros, and D. A. Scheinberg Renal Tubulointerstitial Changes after Internal Irradiation with {alpha}-Particle-Emitting Actinium Daughters J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2677 - 2689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. G. van Schaijk, M. Broekema, E. Oosterwijk, J. E.M. van Eerd, B. J. McBride, D. M. Goldenberg, F. H.M. Corstens, and O. C. Boerman Residualizing Iodine Markedly Improved Tumor Targeting Using Bispecific Antibody-Based Pretargeting J. Nucl. Med., June 1, 2005; 46(6): 1016 - 1022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Singh Jaggi, B. J. Kappel, M. R. McDevitt, G. Sgouros, C. D. Flombaum, C. Cabassa, and D. A. Scheinberg Efforts to Control the Errant Products of a Targeted In vivo Generator Cancer Res., June 1, 2005; 65(11): 4888 - 4895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stein, S. V. Govindan, M. Hayes, G. L. Griffiths, H. J. Hansen, I. D. Horak, and D. M. Goldenberg Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody Clin. Cancer Res., April 1, 2005; 11(7): 2727 - 2734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Sharkey The Direct Route May Not Be the Best Way to Home J. Nucl. Med., March 1, 2005; 46(3): 391 - 394. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Cardillo, H. Karacay, D. M. Goldenberg, D. Yeldell, C.-H. Chang, D. E. Modrak, R. M. Sharkey, and D. V. Gold Improved Targeting of Pancreatic Cancer: Experimental Studies of a New Bispecific Antibody, Pretargeting Enhancement System for Immunoscintigraphy Clin. Cancer Res., May 15, 2004; 10(10): 3552 - 3561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Griffiths, C.-H. Chang, W. J. McBride, E. A. Rossi, A. Sheerin, G. R. Tejada, H. Karacay, R. M. Sharkey, I. D. Horak, H. J. Hansen, et al. Reagents and Methods for PET Using Bispecific Antibody Pretargeting and 68Ga-Radiolabeled Bivalent Hapten-Peptide-Chelate Conjugates J. Nucl. Med., January 1, 2004; 45(1): 30 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Winthrop, S. J. DeNardo, H. Albrecht, G. R. Mirick, L. A. Kroger, K. R. Lamborn, C. Venclovas, M. E. Colvin, P. A. Burke, and G. L. DeNardo Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy Clin. Cancer Res., September 1, 2003; 9(10): 3845S - 3853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Rossi, R. M. Sharkey, W. McBride, H. Karacay, L. Zeng, H. J. Hansen, D. M. Goldenberg, and C.-H. Chang Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy Clin. Cancer Res., September 1, 2003; 9(10): 3886S - 3896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Sharkey, H. Karacay, H. Richel, W. J. McBride, E. A. Rossi, K. Chang, D. Yeldell, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg Optimizing Bispecific Antibody Pretargeting for Use in Radioimmunotherapy Clin. Cancer Res., September 1, 2003; 9(10): 3897S - 3913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kraeber-Bodere, A. Faivre-Chauvet, L. Ferrer, J.-P. Vuillez, P.-Y. Brard, C. Rousseau, I. Resche, A. Devillers, S. Laffont, M. Bardies, et al. Pharmacokinetics and Dosimetry Studies for Optimization of Anti-Carcinoembryonic Antigen x Anti-Hapten Bispecific Antibody-mediated Pretargeting of Iodine-131-labeled Hapten in a Phase I Radioimmunotherapy Trial Clin. Cancer Res., September 1, 2003; 9(10): 3973S - 3981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Sharkey, W. J. McBride, H. Karacay, K. Chang, G. L. Griffiths, H. J. Hansen, and D. M. Goldenberg A Universal Pretargeting System for Cancer Detection and Therapy Using Bispecific Antibody Cancer Res., January 15, 2003; 63(2): 354 - 363. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
